ClinicalTrials.gg
Not yet recruitingNCT06132217Updated Nov 15, 2023

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

A Phase 1/2 interventional study of Simmitinib and SG001 in Advanced Solid Tumor, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
168
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood and voluntarily sign the ICF for this study;
  2. Age of 18-75 years (inclusive);
  3. Dose escalation phase: patients with or cytologically confirmed inoperable or advanced solid tumors;
  4. Dose expansion phase: patients who have failed standard treatment (PD or intolerable toxicity after treatment), have no available standard treatment.According to the previous data, the specific tumor cohort was expanded.
  5. In the expansion phase, patients should agree to provide tissue specimens for detection of expression levels and/or MSI or dMMR status;
  6. At least one according to 1.1;
  7. (ECOG) performance status (PS) score 0-1;
  8. Adequate organ function, defined as:

(ANC) ≥ 1.5 × 10\^9/L; count (PLT) ≥ 100× 10\^9/L; (Hb) ≥ 90 g/L; (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × (ULN) (≤ 5.0 × ULN for patients with liver metastases); Serum total (TBIL) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN; (PT), activated partial thromboplastin time (APTT), international normalized ratio(INR)≤1.5 × ULN; Thyroid Stimulating Hormone (TSH)≤ULN; (LVEF)≥50%; Male and female patients of childbearing age must agree to take effective measures during treatment and within 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received any anti-tumor therapy within 4 weeks prior to the first dose;
  2. Urine protein ≥ ++ and 24 h urine protein > 1.0g at screening period;
  3. Symptomatic central nervous system (CNS) or meningeal metastases;
  4. Patients who have previously received any within 4 weeks before the first use of the study treatment or are expected to received any live attenuated vaccine during the study;
  5. History of allergic reactions attributed to any monoclonal antibody, and uncontrolled history of allergic asthma;
  6. Patients with other types of malignant tumors within 5 years prior to the screening, except for radically resected, non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ, or other carcinoma in situ;
  7. Patients with any active disease requiring systemic therapy within 2 years prior to the first dose;
  8. Patients with bleeding tendency; active bleeding or a history of heavy bleeding within the past 6 months;
  9. Presence of any severe and/or uncontrolled disease before starting treatment;
  10. Any active infection requiring antibiotics or hormones systemic treatment by intravenous infusion within 14 days prior to the first dose;
  11. Dose expansion phase: Prior systemic therapy with or immunoagonists targeting , PD-L1, CTLA-4, etc;
  12. Dose expansion phase: Prior systemic therapy with Antiangiogenic drugs including Anlotinib, Afatinib , Lenvatinib, Sorafenib and Fruquintinib, etc;
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Phase Cohort 1

    Drug: Simmitinib · Drug: SG001

  • Experimental
    Dose Escalation Phase Cohort 2

    Drug: Simmitinib · Drug: SG001

  • Experimental
    Dose Escalation Phase Cohort 3

    Drug: Simmitinib · Drug: SG001

  • Experimental
    Dose Expansion Phase Cohort A

    Drug: Simmitinib · Drug: SG001

  • Experimental
    Dose Expansion Phase Cohort B

    Drug: Simmitinib · Drug: SG001

  • Experimental
    Dose Expansion Phase Cohort C

    Drug: Simmitinib · Drug: SG001

Interventions

  • Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.

  • DrugSG001

    Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Dose Limited Toxicity (DLT)

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)

  2. Dose Escalation Phase: Maximum Tolerated Dose (MTD)

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)

  3. Dose Escalation Phase: Recommended Phase 2 Dose (RP2D)

    Time frame: From Cycle 1 Day 1 to Cycle 1 Day 28(each cycle is 28 days)

  4. Dose Escalation Phase-Incidence rate of Adverse Event (AE).

    Time frame: From first dose to 30 days post the last dose, with approximately 3 years

  5. Dose Expansion Phase - Objective Response Rate (ORR) evaluated by Independent Review Committee (IRC) or investigators in advanced solid tumor based on RECIST 1.1.

    Time frame: Up to approximately 3 years.

Secondary outcomes

  1. Plasma Concentration of simmitinib .

    Time frame: Up to approximately 3 years.

  2. Plasma Concentration of SG001

    Time frame: Up to approximately 3 years.

  3. Immunogenicity Assessments for Anti-drug Antibody

    Time frame: Up to approximately 3 years.

  4. Dose Escalation Phase: ORR

    Time frame: Up to approximately 3 years.

  5. Disease Control Rate (DCR)

    Time frame: Up to approximately 3 years.

  6. Progression-free Survival (PFS)

    Time frame: Up to approximately 3 years.

  7. Overall Survival (OS)

    Time frame: Up to approximately 3 years.

  8. Duration of Objective Response (DOR)

    Time frame: Up to Approximately 3 years.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Jan 2027, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 15, 2023
StartEst.
Jan 30, 2024
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2027
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06132217
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Jan 30, 2024 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Nov 15, 2023

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlonstobart

Start the discussion